Biodesix Achieves Thermo Fisher COE Designation for NGS Diagnostics, Expanding Diagnostic Capabilities.

Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence for NGS diagnostics. The company played a key role in the FDA approval of the Oncomine Dx Express Test for solid tumors. Biodesix plans to expand its molecular diagnostic capabilities through a partnership with Thermo Fisher. The partnership will enhance Biodesix's NGS testing capabilities, particularly in tissue-based profiling. Biodesix will present at the CAP TODAY webinar and the College of American Pathologists Annual Meeting to showcase its NGS precision oncology solution.

Biodesix, Inc. (Nasdaq: BDSX), a leading provider of personalized diagnostic solutions, has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for Next-Generation Sequencing (NGS) diagnostics [1]. This recognition follows the company's instrumental role in the validation of Thermo Fisher's Oncomine Dx Express Test for solid tumors, which was recently approved by the FDA [2].

Biodesix's validation efforts, conducted through its Development Services division, utilized design-controlled laboratory processes and quality management systems. These services exemplify Biodesix's ability to support leading life sciences companies and medical research institutions with scientific and operational capabilities [3].

The partnership between Biodesix and Thermo Fisher aims to advance NGS-based diagnostics and expand Biodesix's molecular diagnostic capabilities, particularly in tissue-based profiling. Biodesix CEO Scott Hutton expressed his enthusiasm about the collaboration, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future” [1].

Upcoming presentations will provide insights into Biodesix's NGS precision oncology solution. These include a webinar on August 27, 2025, and a panel discussion at the College of American Pathologists Annual Meeting on September 15, 2025 [1].

References:
[1] https://www.manilatimes.net/2025/08/19/tmt-newswire/globenewswire/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-excellence-coe-for-ngs-diagnostics/2170400
[2] https://natlawreview.com/press-releases/biodesix-recognized-thermo-fisher-scientific-center-excellence-coe-ngs
[3] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html